{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T17:42:54Z","timestamp":1777398174531,"version":"3.51.4"},"update-to":[{"DOI":"10.1002\/14651858.cd010885.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T00:00:00Z","timestamp":1470614400000}}],"reference-count":35,"publisher":"Wiley","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd010885.pub3","type":"journal-article","created":{"date-parts":[[2016,8,8]],"date-time":"2016-08-08T08:53:21Z","timestamp":1470646401000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Different infusion durations for preventing platinum-induced hearing loss in children with cancer"],"prefix":"10.1002","author":[{"given":"Jorrit W","family":"van As","sequence":"first","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; c\/o Cochrane Childhood Cancer; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henk","family":"van den Berg","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elvira C","family":"van Dalen","sequence":"additional","affiliation":[{"name":"Emma Children's Hospital\/Academic Medical Center; Department of Paediatric Oncology; PO Box 22660 Amsterdam Netherlands 1100 DD"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,8,8]]},"reference":[{"issue":"12","key":"10.1002\/14651858.CD010885.pub3-BIB0001|cit1","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1200\/JCO.1997.15.12.3433","article-title":"NB87 induction protocol for stage 4 neuroblastoma in children over 1 year of age: a report from the French Society of Pediatric Oncology","volume":"15","author":"Coze","year":"1997","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1002\/pbc.20379","article-title":"Long-term renal and hearing toxicity of carboplatin in infants treated for localized and unresectable neuroblastoma: results of the SFOP NBL90 study","volume":"45","author":"Bergeron","year":"2005","journal-title":"Pediatric Blood & Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub3-BIB0003|cit3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/pbc.20673","article-title":"Continuous or repeated prolonged cisplatin infusions in children: a prospective study on ototoxicity, platinum concentrations, and standard serum parameters","volume":"47","author":"Lanvers-Kaminsky","year":"2006","journal-title":"Pediatric Blood & Cancer"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub3-BIB0004|cit4","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/01.mph.0000141348.62532.73","article-title":"Platinum compound-related ototoxicity in children: long-term follow-up reveals continuous worsening of hearing loss","volume":"26","author":"Bertolini","year":"2004","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0005|cit5","unstructured":"Brock P Yoeman L Bellman S Pritchard J Ototoxicity in children treated with cis-platinum (CDDP) for germ cell (GCT) and other tumours Medical and Pediatric Oncology 1987 329 (abstract 138)"},{"issue":"4","key":"10.1002\/14651858.CD010885.pub3-BIB0006|cit6","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1002\/mpo.2950190415","article-title":"Cisplatin ototoxicity in children: a practical grading system","volume":"19","author":"Brock","year":"1991","journal-title":"Medical and Pediatric Oncology"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1097\/MPH.0b013e31815d1d83","article-title":"Hearing loss in pediatric oncology patients receiving carboplatin-containing regimens","volume":"30","author":"Dean","year":"2008","journal-title":"Journal of Pediatric Hematology\/Oncology"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0008|cit8","unstructured":"Eloxatin Summary of Product Characteristics www.sanofi-aventis.co.uk\/products\/Eloxatin_SPC.pdf"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub3-BIB0009|cit9","doi-asserted-by":"crossref","first-page":"744","DOI":"10.7326\/0003-4819-91-5-744","article-title":"Furosemide-induced ototoxicity","volume":"91","author":"Gallagher","year":"1979","journal-title":"Annals of Internal Medicine"},{"issue":"9209","key":"10.1002\/14651858.CD010885.pub3-BIB0010|cit10","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1016\/S0140-6736(00)02044-4","article-title":"Circulating plasma platinum more than 10 years after cisplatin treatment for testicular cancer","volume":"355","author":"Gietema","year":"2000","journal-title":"Lancet"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0011|cit11","unstructured":"GRADEprofiler 3.6.1 2011"},{"issue":"7","key":"10.1002\/14651858.CD010885.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1542\/pir.25-7-224","article-title":"Pediatric audiology: a review","volume":"25","author":"Gregg","year":"2004","journal-title":"Pediatrics in Review"},{"issue":"4","key":"10.1002\/14651858.CD010885.pub3-BIB0013|cit13","doi-asserted-by":"crossref","first-page":"e938","DOI":"10.1542\/peds.2009-1597","article-title":"Auditory late effects of childhood cancer therapy: a report from the Children's Oncology Group","volume":"125","author":"Grewal","year":"2010","journal-title":"Pediatrics"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0014|cit14","unstructured":"Higgins JPT Green S Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011 Available from www.cochrane-handbook.org"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0015|cit15","first-page":"123","article-title":"Late effects of cancer treatment and current protective measures","volume-title":"Cancer in Children","author":"Jenney","year":"2005"},{"issue":"34","key":"10.1002\/14651858.CD010885.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"8588","DOI":"10.1200\/JCO.2004.00.5355","article-title":"Ototoxicity in children receiving platinum chemotherapy: underestimating a commonly occurring toxicity that may influence academic and social development","volume":"23","author":"Knight","year":"2005","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0017|cit17","unstructured":"Kremer LCM Jellema P Leclercq E Noorman JK van Dalen EC Cochrane Childhood Cancer Group About The Cochrane Collaboration (Cochrane Review Groups (CRGs)) 2016, Issue 5. Art. No.: CHILDCA"},{"issue":"8","key":"10.1002\/14651858.CD010885.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.tips.2013.05.006","article-title":"Understanding platinum-induced ototoxicity","volume":"34","author":"Langer","year":"2013","journal-title":"Trends in Pharmacological Sciences"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub3-BIB0019|cit19","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1200\/JCO.2011.39.4254","article-title":"A cautionary tale: dosing chemotherapy in infants with retinoblastoma","volume":"30","author":"Leahey","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010885.pub3-BIB0020|cit20","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1016\/j.ejca.2003.08.009","article-title":"Predicting cisplatin ototoxicity in children: the influence of age and the cumulative dose","volume":"40","author":"Li","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"2","key":"10.1002\/14651858.CD010885.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0022-3476(83)80551-4","article-title":"Hearing loss in children receiving cisplatin chemotherapy","volume":"102","author":"McHaney","year":"1983","journal-title":"Journal of Pediatrics"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0022|cit22","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/b109924_13","article-title":"Auditory late effects of chemotherapy","volume":"150","author":"Meyer","year":"2009","journal-title":"Cancer Treatment and Research"},{"issue":"10","key":"10.1002\/14651858.CD010885.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1200\/JCO.2011.36.9744","article-title":"Carboplatin-associated ototoxicity in children with retinoblastoma","volume":"30","author":"Qaddoumi","year":"2012","journal-title":"Journal of Clinical Oncology"},{"issue":"1","key":"10.1002\/14651858.CD010885.pub3-BIB0024|cit24","first-page":"19","article-title":"Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration","volume":"66","author":"Reddel","year":"1982","journal-title":"Cancer Treatment Reports"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0025|cit25","unstructured":"The Nordic Cochrane Centre, The Cochrane Collaboration Review Manager (RevMan). Version 5.3 2014"},{"issue":"12","key":"10.1002\/14651858.CD010885.pub3-BIB0026|cit26","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1038\/ng.478","article-title":"Genetic variants in TPMT and COMT are associated with hearing loss in children receiving cisplatin chemotherapy","volume":"41","author":"Ross","year":"2009","journal-title":"Nature Genetics"},{"issue":"6","key":"10.1002\/14651858.CD010885.pub3-BIB0027|cit27","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1200\/JCO.1989.7.6.754","article-title":"Hearing loss in children and young adults receiving cisplatin with or without prior cranial irradiation","volume":"7","author":"Schell","year":"1989","journal-title":"Journal of Clinical Oncology"},{"issue":"16","key":"10.1002\/14651858.CD010885.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1016\/j.ejca.2004.08.002","article-title":"Best practice in assessing ototoxicity in children with cancer","volume":"40","author":"Skinner","year":"2004","journal-title":"European Journal of Cancer"},{"issue":"5","key":"10.1002\/14651858.CD010885.pub3-BIB0029|cit29","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009219.pub2","article-title":"Medical interventions for the prevention of platinum-induced hearing loss in children with cancer","author":"As","year":"2012","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"7","key":"10.1002\/14651858.CD010885.pub3-BIB0030|cit30","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009219.pub3","article-title":"Medical interventions for the prevention of platinum-induced hearing loss in children with cancer","author":"As","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010885.pub3-BIB0031|cit31","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010181.pub2","article-title":"Platinum-induced hearing loss after treatment for childhood cancer","author":"As","year":"2016","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"8","key":"10.1002\/14651858.CD010885.pub3-BIB0032|cit32","first-page":"2205","article-title":"Influence of cellular factors and pharmacokinetics on the formation of platinum-DNA adducts in leukocytes of children receiving cisplatin therapy","volume":"7","author":"Veal","year":"2001","journal-title":"Clinical Cancer Research"},{"key":"10.1002\/14651858.CD010885.pub3-BIB0033|cit33","unstructured":"World Health Organization WHO Handbook for Reporting Results of Cancer Treatment WHO offset publication no. 48. Geneva, Switzerland 1979"},{"issue":"12","key":"10.1002\/14651858.CD010885.pub3-BIB0034|cit34","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010885","article-title":"Different infusion durations for preventing platinum-induced hearing loss in children with cancer","author":"As","year":"2013","journal-title":"Cochrane Database of Systematic Reviews"},{"issue":"6","key":"10.1002\/14651858.CD010885.pub3-BIB0035|cit35","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010885.pub2","article-title":"Different infusion durations for preventing platinum-induced hearing loss in children with cancer","author":"As","year":"2014","journal-title":"Cochrane Database of Systematic Reviews"}],"updated-by":[{"DOI":"10.1002\/14651858.cd010885.pub4","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2018,7,5]],"date-time":"2018-07-05T00:00:00Z","timestamp":1530748800000}}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full\/10.1002\/14651858.CD010885.pub3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,9]],"date-time":"2021-08-09T22:49:41Z","timestamp":1628549381000},"score":1,"resource":{"primary":{"URL":"https:\/\/doi.wiley.com\/10.1002\/14651858.CD010885.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Childhood Cancer Group","sequence":"additional","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,8,8]]},"references-count":35,"URL":"https:\/\/doi.org\/10.1002\/14651858.cd010885.pub3","relation":{"new_version":[{"id-type":"doi","id":"10.1002\/14651858.CD010885.pub4","asserted-by":"object"}]},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,8]]}}}